Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.

W, Shimizu; Y, Kubota; Y, Hoshika; K, Mozawa; S, Tara; Y, Tokita; K, Yodogawa; YK, Iwasaki; T, Yamamoto; H, Takano; Y, Tsukada; K, Asai; M, Miyamoto; Y, Miyauchi; E, Kodani; M, Ishikawa; M, Maruyama; M, Ogano; J, Tanabe

doi:10.1186/s12933-020-01127-z

Public

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.

Shared by NobleBlocks on Sep 25, 2020 • 12:00 AM UTC

Authors:

Shimizu W

Kubota Y

Hoshika Y

Abstract

<h4>Background</h4>Protection from lethal ventricular arrhythmias leading to sudden cardiac death (SCD) is a crucial challenge after acute myocardial infarction (AMI). Cardiac sympathetic and parasympathetic activity can be noninvasively assessed using heart rate variability (HRV) and heart rate tur...

Subject

Acute myocardial infarction

Randomized controlled trial

heart rate variability

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!